$0.74
+0.06 (+8.26%)
Open$0.69
Previous Close$0.68
Day High$0.74
Day Low$0.60
52W High$8.49
52W Low$0.72
Volume—
Avg Volume203.6K
Market Cap14.89M
P/E Ratio—
EPS$-0.89
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+2,972.5% upside
Current
$0.74
$0.74
Target
$22.62
$22.62
$15.82
$22.62 avg
$24.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 11.82M | 10.52M | 11.40M |
| Net Income | 3.06M | 2.28M | 2.66M |
| Profit Margin | 25.9% | 21.7% | 23.3% |
| EBITDA | 4.32M | 3.67M | 4.36M |
| Free Cash Flow | 3.21M | 3.03M | 2.01M |
| Rev Growth | +9.7% | +22.7% | +8.4% |
| Debt/Equity | 0.16 | 0.13 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |